RT Generic
T1 Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD".
A1 Ampuero, Javier
A1 Gallego-Duran, Rocio
A1 Romero-Gomez, Manuel
K1 Fibrosis
K1 Humans
K1 Liver Cirrhosis
K1 Non-alcoholic Fatty Liver Disease
AB Mao  et al. suggest the modification of several parameters employed in the paper for the diagnosis of the dysmetabolic-related outcomes. First, these authors propose using glucose intolerance tests instead of a diagnosis of type 2 diabetes mellitus as an outcome measure . We fully agree with the correspondents about the usefulness of the early detection of glucose intolerance due to the capacity to prevent further events in patients at risk of progressing to diabetes mellitus . However, these tests, such as oral glucose tolerance test , are not suitable for a wide screening of patients because they are time -consuming (2 hours duration) and not cost -effective in this scenario.3 Further, these tests are typically carried out in dedicated units, such as Endocrinology units
PB Elsevier BV
YR 2021
FD 2021
LK http://hdl.handle.net/10668/16846
UL http://hdl.handle.net/10668/16846
LA en
NO Ampuero J, Gallego-Durán R, Romero-Gómez M. Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD". J Hepatol. 2021 Apr;74(4):971-972.
DS RISalud
RD Nov 6, 2025